Patients will be randomized into two groups (1/1) during one year: * 40 mg adalimumab subcutaneously (sc) every other week * placebo The effect on x-rays and clinical parameters will be evaluated.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Evaluation of x-rays
Evaluation of clinical parameters (pain, daily functioning, etc.)